SenesTech Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SenesTech (NASDAQ: SNES) announced that its Board of Directors granted an inducement equity award to John Karabees in connection with his appointment as Executive Vice President, Sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SenesTech (NASDAQ: SNES) announced that its Board of Directors granted an inducement equity award to John Karabees in connection with his appointment as Executive Vice President, Sales. The award was made under the 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The grant, dated August 25, 2026, is a nonstatutory stock option to purchase 108,470 shares of common stock at an exercise price of $1.19 per share, equal to the fair market value on the grant date. The option vests in 12 equal quarterly installments starting from July 1, 2026 and becomes fully vested on the third anniversary of that commencement date, subject to continued service. The award was approved by unanimous written consent of the Board, with a majority of independent directors.
Positive
- Inducement option grant for 108,470 shares at $1.19 aligns with market price
- Three-year quarterly vesting schedule supports executive retention and long-term focus
Negative
- Stock option for 108,470 shares introduces incremental potential dilution to shareholders
Details
News Market Reaction – SNES
On Aug 28, the first trading day after this news, SNES closed 0.91% below the previous close. Relative volume reached 4.5x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 28 session.
Key Figures
- Option Shares
- 108,470 shares
- Inducement award
- Exercise Price
- $1.19 per share
- Option grant on Aug. 25, 2026
- Grant Date
- Aug. 25, 2026
- Inducement award
- Vesting Schedule
- 12 equal quarterly installments
- Subject to continued service
- Vesting Commencement
- July 1, 2026
- Option vesting schedule
- Full Vesting
- Third anniversary
- Of the vesting commencement date
- Nasdaq Listing Rule
- 5635(c)(4)
- Inducement equity award
Historical Context
-
Company announced participation in the Lytham Partners investor summit webcast.
-
Record revenue and gross margin were reported alongside continuing quarterly losses.
-
New B2B assessment services expanded implementation support and potential revenue opportunities.
-
Online subscribers more than doubled as e-commerce growth accelerated during the quarter.
-
Company scheduled release of second-quarter financial results and its follow-up conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nonstatutory stock option financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The award was granted under the SenesTech, Inc. 2026 Inducement Plan as a material inducement to Mr. Karabees entering into employment with SenesTech, in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement award, granted on Aug. 25, 2026, consists of a nonstatutory stock option to purchase 108,470 shares of SenesTech common stock at an exercise price of
The option will vest and become exercisable in 12 equal quarterly installments measured from a vesting commencement date of July 1, 2026, subject to Mr. Karabees' continued service with the Company through each applicable vesting date. The option will be fully vested and exercisable on the third anniversary of the vesting commencement date.
The award was approved by unanimous written consent of the Company's Board of Directors, a majority of whose members are independent directors under Nasdaq listing standards.
About SenesTech
SenesTech is the leader in rodent birth control and sustainable rodent population management, with a mission to support a healthier environment through the responsible management of animal pest populations. The Company's Evolve® and ContraPest® fertility control solutions, along with its assessment and monitoring services, target reproduction to help reduce rodent populations. SenesTech serves consumer and professional markets with proven approaches that can be used independently or as part of an integrated pest management (IPM) program.
CONTACT:
Investors: Robert Blum, Lytham Partners, LLC, (602) 889-9700, senestech@lythampartners.com
Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., (928) 779-4143
View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-302861052.html
SOURCE SenesTech, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.